The Complete Ipamorelin & CJC-1295 Stack Guide

If you have been looking into growth hormone optimization, you have probably encountered a maze of peptides, dosing protocols, and conflicting advice. Two names keep surfacing in the research: Ipamorelin and CJC-1295. These compounds are often stacked together, and for good reason — the combination targets growth hormone (GH) release through two complementary pathways.

This guide breaks down what the science actually says, how each compound works, and how to track your protocol if you and your healthcare provider decide this approach is right for you.

Why Growth Hormone Matters for Longevity

Growth hormone plays a foundational role in tissue repair, muscle maintenance, and metabolic regulation. After age 30, GH secretion declines roughly 1-2% per year. By the time someone reaches 60, daily GH output may be half of what it was in their twenties.

This decline matters because GH influences:

• Body composition — muscle preservation and fat distribution
• Bone density — skeletal integrity over time
• Sleep quality — GH is released in pulses during deep sleep
• Tissue repair — recovery from exercise and daily wear

Research indicates that sustained lower GH levels are associated with reduced lean mass, increased body fat, and diminished tissue repair capacity. This does not mean GH therapy is right for everyone — but it does mean understanding your GH landscape matters if you are serious about healthspan optimization.

Insulin-like growth factor 1 (IGF-1) is the primary mediator of GH effects in tissues. When GH is released from the pituitary, it stimulates the liver to produce IGF-1, which then drives tissue growth and repair. This is why IGF-1 levels are often used as a proxy marker for GH activity.

Ipamorelin — The Selective Growth Hormone Secretagogue

Ipamorelin is classified as a growth hormone secretagogue (GHS). That means it stimulates GH release by acting on the ghrelin receptor (GHSR), the same receptor that natural hunger hormones activate.

What sets Ipamorelin apart from earlier GHS compounds is its selectivity. It was the first GHS specifically designed to amplify the natural GH pulse without causing significant release of other hormones like cortisol, prolactin, or ACTH. In a 2005 study published in The Journal of Pharmacology and Experimental Therapeutics, researchers found that Ipamorelin elevated GH levels in healthy subjects while maintaining a favorable selectivity profile compared to earlier secretagogues.

How It Works

Ipamorelin binds to the GHSR on somatotroph cells in the pituitary gland. This binding triggers a signal cascade that prompts the cells to release stored GH into the bloodstream. Unlike exogenous GH (which delivers a sustained, non-physiologic GH level), Ipamorelin amplifies your body existing pulse pattern — particularly the pulses that occur during deep sleep and after exercise.

The compound is a 5-amino acid peptide. Its relatively simple structure is part of what makes it selective — it activates the GH release pathway without broadly stimulating other hormonal axes.

What the Research Shows

The landmark 2005 study by Jette et al. demonstrated that Ipamorelin administered to healthy adults produced a dose-dependent increase in GH secretion with minimal off-target effects. The selective mechanism was the key finding: earlier GHS compounds often caused unwanted cortisol or prolactin spikes; Ipamorelin did not at comparable doses.

CJC-1295 — The GHRH Analog

CJC-1295 works differently. It is a growth hormone-releasing hormone (GHRH) analog — meaning it mimics the action of GHRH, the hormone naturally produced by the hypothalamus.

GHRH acts on somatotroph cells via a different receptor than the ghrelin receptor. When GHRH binds to its receptor, it stimulates GH synthesis (not just release of stored GH) and prolongs the pulsatile pattern of GH secretion.

DAC vs. No-DAC

CJC-1295 comes in two forms:

• CJC-1295 with DAC (Drug Affinity Complex) — the DAC component extends the half-life, creating sustained IGF-1 elevation over days
• CJC-1295 no-DAC — shorter half-life, produces more acute GH pulses that more closely mimic natural physiology

Most peptide optimization protocols in the non-clinical space use the no-DAC version for this reason: it produces a GH pulse pattern closer to natural secretion, without the prolonged elevated state that DAC versions create.

A 2006 study by Teichman et al. found that CJC-1295 administered to healthy adults produced significant and sustained increases in GH and IGF-1 levels, with the magnitude depending on dose and frequency. A follow-up study by Samirez et al. confirmed similar IGF-1 elevation with once-daily administration. Both studies noted that the elevation was sustained above baseline for an extended period compared to native GHRH.

How It Works

CJC-1295 (no-DAC) binds to GHRH receptors in the pituitary, triggering two effects:

1. Rapid GH release — from existing stored GH pools (similar to Ipamorelin)
2. Increased GH synthesis — over days to weeks, more GH becomes available for future pulses

This dual mechanism is why CJC-1295 is often described as having both an immediate and a sustained effect on GH levels.

Why Stack Them — The Complementary Pathways Rationale

Ipamorelin and CJC-1295 target GH release through two distinct receptor pathways:

Using both together more closely mirrors the body natural dual-control of GH: the hypothalamus releases GHRH to stimulate synthesis and pulse generation, while ghrelin signals from the stomach modulate the amplitude of those pulses, particularly around meals and sleep.

Research on stacked GHRH + GHS approaches has shown more physiologic GH elevation patterns than single-agent use. In short: the two compounds work on different arms of the same system, and stacking them produces a more complete stimulation of the GH axis.

Practical Protocol Considerations

If you are working with a healthcare provider and they have determined that a GH-optimization protocol is appropriate for your situation, here is what typical dosing looks like for these two compounds:

Ipamorelin:

• Typical dose range: 100-300 micrograms (mcg)
• Frequency: 1-2 times daily
• Common timing: before sleep, or pre/post exercise

CJC-1295 (no-DAC):

• Typical dose range: 100 mcg
• Frequency: 1-2 times daily
• Common timing: same schedule as Ipamorelin

Cycle considerations: Many protocols run in the 8-12 week range, followed by a break period to allow the GH axis to reset. Cycle length and post-cycle protocols should be discussed with your healthcare provider, as individual responses vary.

Important Notes on Sourcing and Administration

Both Ipamorelin and CJC-1295 are peptides that must be sourced from reputable, third-party-tested pharmacies or compounding facilities. Purity and sterility matter enormously — contamination or incorrect concentration is a real risk in the unregulated peptide space. Always verify third-party testing and avoid sources that do not provide Certificates of Analysis.

Administration is subcutaneous (SC) injection — meaning under the skin, typically in abdominal or thigh fat. Proper injection technique and sterile handling are non-negotiable.

How to Track Your Protocol in Vivy

Consistent tracking is what separates a hobbyist from someone who can actually measure whether a protocol is working. Here is the framework:

Log each compound as a separate protocol entry:

• Record compound name, dose (in mcg), and exact time
• Note the injection site (abdominal vs. thigh) to track site rotation
• Log before/after subjective energy, appetite, and sleep quality

Track these markers weekly:

• Sleep quality score (1-10)
• Morning energy level
• Exercise recovery perception
• Body composition (scale weight + waist measurement at minimum)

Track these markers monthly:

• IGF-1 via blood work (this requires a lab order from your provider — Vivy cannot interpret results for you, but you can log the values to see trends over time)
• Fasting glucose and HbA1c
• Lipid panel (GH optimization can affect lipid metabolism)

Correlate timing with outcomes: If you inject at 10 PM versus 8 PM, note the difference in your morning readiness and sleep architecture. Over 4-6 weeks, patterns will emerge.

The Data You Collect Today Is Evidence You Cannot Manufacture Later

If you are running a GH optimization protocol — whether for longevity, body composition, or recovery — the numbers you track are the only way to know if it is working. Blood work tells you where you stand. Daily logs tell you what changes as a result of what you did.

Vivy protocol tracking is built exactly for this: not just logging that you took something, but understanding what happened next.

Before you start: log your baseline. Know your IGF-1, your fasting glucose, your current body composition. Then run your protocol with precision and track every variable that matters to you.

In 90 days, you will either have a dataset that shows you what your GH axis did under stimulation — or you will not. That difference is the difference between guessing and knowing.